We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Riddler. Val only closed up 6% in the end
Val up 10% again
Not sure how you can force someone to answer a question? I’m all ears though??
Repeat business from previous clients / customers. According to time scales in the RNS’s that work has been concluded. Hence previous not current!
ooofffttt72 "The points raised below were submitted to the company. Only JM can tell you why he did not respond."
And only you can say why you didn't press him for an answer?
According to the announcements we have more repeat business than one off contracts and those one offs may well repeat anyway. The overall picture is upward progress from one customer to many .
The points raised below were submitted to the company. Only JM can tell you why he did not respond. Truro - companies both large and small have used our services in the past - not so sure about the usually come back for more part. It looks like we have had multiple contracts from Merck (last one Dec 2021 for 6 months) and Bicycle (May 2021 for 6 months). Nothing from them since. My point being we have signed 2 contracts in YTD 2022 and none of them have been repeat business.
This situation is sadly all to common and I'm sure we all have been affected with friends and loved ones suffering due to oncology delays during Covid
https://www.bbc.co.uk/news/health-62483323
Which year? 2022 or 2023?
Jim stated there is no direct correlation between size of client and size of contract?
Funny. Been pointing this out here for a while.
Exactly right Laura, Those questions should have been put directly to JM at the presentation but he failed to do so because basically he's an attention seeker - just like the Donald!
Apart from last year, when we were adversely effected by Covid, we've made continuously excellent progress across the board since his JM's arrival. As he said in the presentation - when he came here we were basically a one customer company and we now have a growing range of both large and small companies that usually come back for more which is testament to the product and the efficiency of the company.
This is going to break
Hi oopft
Hope you don't mind me asking but have you emailed or rang him with your points of view?
Well Jim. Thanks for taking the time the other week to give us all 30 mins and provide an update on what has been an abysmal performance for 2022 to date. You reiterated the pipeline was the best it’s ever been. Again I will ask you why next to no conversion? You mentioned we have enough cash to last 2 years. Based on what? Overheads (headcount) is increasing without an increase in sales - you wouldn’t be stretching the truth here again would you? And finally did the large pharma you eluded to deliver a large contract in terms of revenue? As you stated there is no direct correlation between size of client and size of contract. Misleading people again possibly. What were the targets in terms of revenue and expenditure for this year - care to enlighten us??
Article on page 4 of yesterdays Times. Professor Kristian Helin the CEO of the Institute of Cancer Research is leading a call for all Cancer patients to have both their own DNA tests and also their Tumors DNA tested to improve drug selection and also dosage levels. Signatories include Cancer Research UK and the British Pharmaceutical Association. Apparently the NHS is currently partially doing this but not routinely. Sounds right up PYC's street!
That’s pure speculation Laura2022. PYC has net asset value of about £1M and market cap about twice that. Nothing to suggest it’s going to be worth any more at all I’m afraid!
For at least the past decade, patients, advocacy groups, academic oncologists, representatives of drug companies, and regulators have been calling for change to the prevailing dosing paradigm rooted in cytotoxic chemotherapeutics.2 The FDA and others have also led efforts to educate key stakeholders regarding methods of dose optimization for targeted therapies. Despite broad awareness of the issue of poor dose selection for oncology drugs, there has not been widespread implementation of new approaches to dose optimization.
In 2021, the FDA’s Oncology Center of Excellence established Project Optimus to take a more proactive role in changing the dosing paradigm in oncology.3 This project brings together scientists with expertise in clinical pharmacology, medical oncology, biostatistics, pharmacology/toxicology, and other areas from across the FDA and outside the agency to address how best to select doses for oncology drugs. Its mission is to ensure that doses of oncology drugs are optimized to maximize efficacy as well as safety and tolerability
This article was posted on another board, mabe relevant to PYC ?
https://ascopost.com/issues/may-10-2022/how-to-get-the-dose-right/
Share 4. I've decided not gonna comment on anything anymore. I'm getting too old for it all. Best wishes.
Sorry not biggest, one of the biggest...
Sienna, I didn't say that, the biggesst investor in VAL said that, read the post again.
King homer. I've purchased more at these low levels during this week. Do u think I lack the intelligence to notice a bargain????
Share 4. You said you should have shorted pyc In your earlier comment and then contradict yourself later. Cretin!!!
Has anyone tried shorting PYC?????
Coz if you knew PYC or tried you would have know that no broker or platform will allow you to do it !!! Due to volume and low marketing cap A it’s been like this for years
Sienna - why are you actually still here your share holding is now worth £46?? I’ll give to £100 to sell and do one A seriously wasting Your time here and effectively showing any future investors how immature this board is with sheer lack of knowledge
Bit irrational Sienna, I wouldn't try to short a small illiquid stock like this but each to their own.
VAL looks undervalued and has been moving up and down on no news for the last week or so, I got some at 11.2 earlier today. One of the declared VAL investors (Slater) posting as "Viera" posted the following:
I looked at both Val and pyc when both were 7p a while back
I concluded pyc was worth about 3p and Val 80p so I bought Val (should’ve shorted pyc !!)
Also there are a lot of desperate bulls in PYC who end up cross ramping which is a huge desperation signal.
I wouldn’t touch pyc with a barge pole
Valirx is moving as well on no news. maybe the 201 deal is finally over the line?